Are CV studies worth it for diabetes meds? After Merck and Sanofi's recent successes, some say no

Earlier this week, diabetes drugmakers Merck ($MRK) and Sanofi ($SNY) rolled out data showing their meds--Januvia and Lyxumia, respectively--passed heart safety tests, turning up no red flags in postmarketing studies. And now, some industry watchers are wondering whether those large, expensive trials--which aren't long enough to establish long-term outcomes--were worth it. Story | More on Januvia | More on Lyxumia

Suggested Articles

Sixteen years after it was approved, the FDA has ordered that heartburn drug Zantac and its generics be removed from the market.

In a non-randomized study in China, Avigan cleared virus after a median 4 days, significantly shorter than the 11 days observed for AbbVie's Kaletra.

Pfizer's 1.1-million-square-foot sterile injectables plant in Visakhapatnam has been criticized by the FDA for poor quality testing.